相关临床试验
7
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
6
85.7%
撤回
1
14.3%
暂无批准数据
- Bright Minds Biosciences completed a $175 million public offering to fund clinical trials for its lead epilepsy drug BMB-101, which targets childhood epilepsy through selective serotonin 5-HT2C receptor activation. - The company's BMB-101 compound is designed to avoid the cardiac and psychedelic side effects that plagued previous drugs like fenfluramine by selectively targeting the 2C receptor while avoiding 2A and 2B receptors. - Phase II trial results for BMB-101 in developmental epileptic encephalopathies and absence epilepsy are expected around the end of this year, with the company's stock having appreciated approximately 5,000% over the past 12 months. - Recent acquisitions in the epilepsy space, including Lundbeck's $2.6 billion purchase of Longboard Pharmaceuticals for a similar serotonin 2C mechanism drug, highlight strong industry interest in this therapeutic approach.
- Ananda Pharma announced plans to delist from AQSE Growth Market and transition to private company status, citing high regulatory costs and limited liquidity that consumed resources better deployed in clinical development. - The company terminated its involvement in a landmark NHS-funded epilepsy trial at UCL and Great Ormond Street Hospital after contractor supply issues, allowing focus on its lead asset MRX1 for pain indications. - Phase 1 results for MRX1 showed favorable safety profile with only mild adverse events across 20 participants, supporting advancement to Phase 2 trials for endometriosis and chemotherapy-induced peripheral neuropathy starting Q1 2026.
- Design Therapeutics has appointed industry veteran Justin Gover to its Board of Directors, bringing over 25 years of biotechnology leadership experience to the clinical-stage genetic disease company. - Gover previously served as founding CEO of GW Pharmaceuticals for over two decades, leading the company through its $7 billion acquisition by Jazz Pharmaceuticals in 2021 and the successful commercialization of Epidiolex for childhood epilepsies. - The appointment comes as Dr. Arsani William stepped down from the board, having provided strategic guidance since 2021 including through the company's IPO and clinical pipeline advancement. - Design Therapeutics is developing GeneTAC gene targeted chimera small molecules to modulate disease-causing gene expression, with clinical programs targeting Friedreich ataxia and Fuchs endothelial corneal dystrophy.
- Cardiol Therapeutics' cannabidiol-based therapy CardiolRx failed to meet co-primary endpoints in the Phase II ARCHER trial for myocarditis, with extracellular volume reduction missing statistical significance (p=0.0538). - The company's stock dropped 20% from $1.35 to $1.07 following the trial results, despite CEO David Elsley expressing satisfaction with the outcomes. - While CardiolRx showed some cardiac improvements including significant left ventricular mass reduction, it failed to improve global longitudinal strain scores compared to placebo. - The company continues advancing its Phase III MAVERIC trial for recurrent pericarditis and plans to integrate ARCHER findings into broader clinical development strategy.
- MMJ International has developed MMJ-001, a pharmaceutical-grade cannabis drug containing natural THC and CBD extracts specifically formulated for chorea associated with Huntington's Disease. - The investigational drug has received FDA Orphan Drug Designation, providing seven years of market exclusivity and accelerated review pathways for a condition affecting tens of thousands of Americans. - MMJ-001 is progressing toward Phase II FDA-sanctioned human trials after successful preclinical investigations and represents the only known natural THC/CBD softgel in the FDA pipeline for Huntington's Disease. - The company differentiates its approach from synthetic alternatives by preserving the full therapeutic potential of cannabis through natural full-spectrum extracts manufactured under GMP conditions.
- Xenon Pharmaceuticals has appointed Darren Cline as Chief Commercial Officer to lead commercial strategy for azetukalner, the company's lead Phase 3 candidate targeting epilepsy, major depressive disorder, and bipolar depression. - Cline brings over 30 years of biopharmaceutical commercial experience, including successful launches of Epidiolex at GW Pharmaceuticals and Adcetris at Seagen. - The appointment comes as Xenon prepares for Phase 3 azetukalner data expected in early 2026, positioning the company for its first potential commercial launch in epilepsy. - Azetukalner is a novel Kv7 potassium channel opener currently in Phase 3 trials for epilepsy and major depressive disorder, with a Phase 3 trial in bipolar depression planned for 2025.
- Jazz Pharmaceuticals CEO Bruce Cozadd has announced his retirement after leading the company since 2009, though he will remain as board chairman after the transition. - Under Cozadd's leadership, Jazz grew significantly, completing a $7 billion acquisition of GW Pharmaceuticals and achieving annual revenues approaching $4 billion through key products Xywav and Epidiolex. - The company has initiated a comprehensive succession search expected to conclude within one year, considering both internal and external candidates while maintaining business momentum.
- The U.S. tuberous sclerosis drug market is expected to grow from $237.2 million in 2022 to $1.25 billion by 2030, driven by FDA approvals of new treatments and increasing disease prevalence. - FDA-approved treatments include Afinitor (everolimus) for patients aged 2 and above, approved in 2018, and Epidiolex (cannabidiol) for patients aged 1 and above, approved in 2020. - mTOR inhibitors are gaining significant traction in treatment protocols, showing effectiveness for internal tumors and skin lesions, with FDA approval for treating lung complications like Lymphangioleiomyomatosis (LAM) in 2015.
- Jazz Pharmaceuticals has agreed to acquire GW Pharmaceuticals for $7.2 billion, marking a significant expansion into cannabis-derived medicines and creating a leader in neuroscience therapeutics. - GW's flagship product Epidiolex, the first FDA-approved cannabis-based medicine, achieved $510 million in sales in 2020 and holds patent protection until at least 2035. - The acquisition diversifies Jazz's portfolio beyond its narcolepsy drug Xyrem and includes GW's late-stage pipeline candidate nabiximols, currently in Phase 3 trials for MS spasticity.
